GlassScriptPhysician profile
Archana Sinha
NPI 1386932978
$2,004.73
in general payments reported to CMS, 2019-2025
22 companies · $356 in 2025
The $356 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2020: $182 · 2021: $406 · 2022: $162 · 2023: $14.28 · 2024: $421 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $790.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $294.35 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $245.59 | 2019-2024 | |
| Biotronik INC. | $244.26 | 2024-2025 | Amvia Edge, Acticor 7 Vr-T Dx, Biomonitor |
| Amgen INC. | $174.25 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $142.82 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $133.77 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.41 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $120.99 | 2021-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $101.68 | 2021-2025 | Verquvo |
| Jazz Pharmaceuticals INC. | $75.94 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $62.68 | 2021-2022 | |
| Mckesson Medical-Surgical, INC. | $43.83 | 2024 | |
| Abbott Laboratories | $41.36 | 2021 | |
| Boston Scientific Corporation | $36.45 | 2025 | Watchman Access System |
| Irhythm Technologies, INC. | $35.82 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Preventice Services, LLC | $23.71 | 2021 | |
| Edwards Lifesciences Corporation | $20.66 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $18.49 | 2019 | |
| Grifols USA, LLC | $18.25 | 2022 | |
| Esperion Therapeutics, INC. | $15.66 | 2025 | Nexletol |
| Baxter Healthcare | $13.90 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Mylan Specialty L.P. | $12.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Archana Sinha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.